Clinical Trial Update: Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 safety and efficacy study of an anti-B7-H3 CAR-T cell therapy for recurrent glioblastoma, sponsored by Beijing Ti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Anti-B7-H3 CAR-T Cell Therapy (B7-H3-targeted CAR-T cell therapy)

Snippet

Sponsor: Beijing Tiantan Hospital | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING